Abstract
Fasciola hepatica infections cause huge economic losses to livestock production and are a serious problem in human and veterinary medicine. The main difficulty in the control of infections is progressing drug resistance. Moreover, pharmacological therapy is expensive and harmful for the environment. The best way of prophylaxis against infections seems to be vaccination. A new generation of vaccines could be the best possible way of controlling fasciolosis. This paper is focused on first vaccination trials based on a new vaccine candidate antigen, F. hepatica phosphoglycerate kinase (FhPGK) performed on a rat model. We obtained protection levels ranging from 0% to 69% depending on the way of delivery and form of vaccine.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
